BackChromocell Therapeutics Overview

Chromocell Therapeutics Current Cash

Chromocell Therapeutics's current cash is $24M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$24.19M
↑ 40784.20% YoYΔ $24.13M vs prior year quarter

Peer trimmed avg / median

Loading

Chromocell Therapeutics Current Cash History

Loading

Chromocell Therapeutics vs. peers: Current Cash Comparison

Loading

Chromocell Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Chromocell Therapeutics (CHRO) FAQ

As of the most recent data (June 2026), CHRO shows a current cash of $24M. That compares with $59K in the prior-year period — up 40784.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CHRO's current cash is now $24M (was $59K) — a 40784.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Chromocell Therapeutics is outperforming or lagging.

Tracking CHRO's current cash over time shows whether Chromocell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $24M That compares with $59K in the prior-year period — up 40784.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Chromocell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $24M) with ownership activity and broader fundamentals.